A trial fibrillation (AF) is common, and its incidence is expected to increase during the next decade. The prevalence of AF in the United States was estimated to range from 3 to 6 million in 2010 and is expected to rise to between 6 and 12 million in 2050. 1 Patients with AF, compared with those without AF, are at higher risk of all-cause and cardiovascular death. 2 Although treatment with effective oral anticoagulants can reduce the risk of death in patients with AF, 3 mortality still remains 1 of the most frequent adverse outcomes. [4] [5] [6] Among patients with AF, biomarkers can aid in risk stratification for cardiovascular events and also for total and cardiovascular death and major bleeding. It is unclear whether risk stratification for specific causes of death can be improved by the use of biomarkers. [7] [8] [9] Cardiac troponin T measured with high-sensitivity assays (cTnT-hs) is an established marker of myocardial damage. Among patients with AF, cTnThs improves risk stratification for stroke, bleeding, and cardiovascular mortality beyond routinely used clinical risk scores. 8, 10 Similarly, NT-proBNP (N-terminal pro-Btype natriuretic peptide; a marker of cardiomyocyte stress) and interleukin-6 (a marker of inflammation) have demonstrated prognostic utility among patients with AF. 11, 12 Growth-differentiation factor-15 (GDF-15) is an emerging biomarker of inflammation and oxidative stress that has demonstrated prognostic utility for a variety of outcomes across a spectrum of cardiovascular diseases, including AF. [13] [14] [15] Although these 4 biomarkers have demonstrated significant prognostic utility for total and cardiovascular death, 9 the use of these biomarkers, both individually and in combination, in the prediction and risk stratification for cause-specific death has not been investigated. Using data from the ARISTOTLE trial (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation), we evaluated (1) the distribution of cause-specific deaths, (2) the clinical variables and biomarkers associated with cause-specific deaths, and (3) the utility of biomarkers to improve risk stratification of cause-specific death.
METHODS
The data, analytic methods, and study materials will not be made available to other researchers for purposes of reproducing the results or replicating the procedure. The details and results of the ARISTOTLE trial have been previously published. 5 Briefly, ARISTOTLE was a double-blind, double-dummy, randomized clinical trial that enrolled 18 201 patients with AF and ≥1 CHADS 2 risk factor for stroke or systemic embolism (SE). Patients were randomized to warfarin or apixaban, and the trial's primary end point was stroke or SE. The median follow-up was 1.8 years. Among patients enrolled in the ARISTOTLE trial, 14 798 had ≥1 of the 4 biomarkers (high sensitivity troponin T, NT-proBNP, GDF-15, and interleukin-6) measured. The median length of follow-up was 1.9 years for participants in the biomarker cohort. Approval by the appropriate ethics committees was obtained at all sites. All patients provided written informed consent. The analyses were supported by Bristol-Myers Squibb, Pfizer, and grants from Roche Diagnostics. The funding sources were given the opportunity to review and comment on the final version of the manuscript. The first and senior authors and the statisticians were responsible for and accordingly had full access to the database. The decision on submission was made by all coauthors.
Study End Points
Death from any cause was a key secondary efficacy outcome in the ARISTOTLE trial. The primary end points for this study included cause-specific cardiovascular death, which included sudden cardiac death, heart failure death, and stroke/SE death. Bleeding death and other noncardiovascular deaths were also evaluated. Although stroke/SE included both ischemic and hemorrhagic strokes, the specific stroke-related deaths were not adjudicated. Bleeding deaths included nonstroke-related intracranial bleeding (eg, subdural hematoma). A blinded clinical events committee using prespecified criteria centrally evaluated all outcome events and causes of death.
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Clinical Perspective
What Is New?
• Among patients with atrial fibrillation and cardiovascular risk factors, we evaluated the role of biomarkers (high-sensitivity troponin T, growth differentiation factor-15, N-terminal pro-B-type natriuretic peptide, and interleukin-6) in prognosticating for specific causes of death.
• Using data from the ARISTOTLE trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation), we identified that sudden cardiac death was the most commonly adjudicated cause of cardiovascular death, followed by heart failure and stroke/systemic embolism-related deaths.
• Biomarkers were some of the strongest predictors of cause-specific death and may improve the ability to discriminate among patients' risks for different causes of death.
What Are the Clinical Implications?
• Our results suggest that among anticoagulated patients with atrial fibrillation and cardiovascular risk factors, stroke/systemic embolism is not the most common cause of death.
• Among patients anticoagulated for atrial fibrillation, interventions and risk factor modifications aimed at reducing mortality beyond stroke death will be important in the efforts to improve the outcomes of patients with atrial fibrillation.
• In addition, our findings suggest that biomarkers might be useful to guide interventions focusing on the prevention of fatal events other than stroke and targeting treatment and prevention of cardiac risk factors such as heart failure that might improve these patients' survival. 
Statistical Analysis
Demographics and other baseline characteristics were described using frequencies for categorical variables and median and 25th and 75th percentiles for continuous variables. Among all patients enrolled in the ARISTOTLE trial, Cox proportional hazards regression models were used to identify clinical variables independently associated with each specific cause of death. Subsequently, among patients with biomarker data, Cox proportional hazards regression models were used to identify biomarker and clinical variables associated with each specific cause of death. The multivariable models were based on a prioritized set of risk factors that were identified in previous publications, 9, 17, 18 and they included the following baseline characteristics specified for each death: age, body mass index, glomerular filtration rate, systolic blood pressure, heart rate, sex, smoking history, type of AF, history of diabetes mellitus, prior stroke/SE/transient ischemic attack, history of congestive heart failure, hypertension, history of myocardial infarction/ percutaneous coronary intervention/coronary artery bypass surgery/peripheral artery disease, hemoglobin, history of bleeding, white blood cell count, statin use at baseline, angiotensinconverting enzyme inhibitors/angiotensin-receptor blockers at baseline, amiodarone use at baseline, use of nonsteroidal antiinflammatory drugs or antiplatelets at baseline, randomized treatment group, geographic region (included for adjustment only), or warfarin/vitamin K antagonist status (naïve versus experienced). The variables used in each model were based on the limitations in the number of events (Table II in the onlineonly Data Supplement). The proportional hazards assumption was evaluated by plotting Schoenfeld residuals against rank time and fitting a smooth curve. The analyses for the clinical variables associated with cause-specific death included data from all 18 201 intention-to-treat patients enrolled in the ARISTOTLE trial. The analyses for the biomarker variables and clinical variables associated with cause-specific death included data from the 14 798 intention-to-treat patients with available biomarker data. A complete case analysis was implemented as <2% of patients were excluded because of incomplete set of covariates. As a sensitivity analysis, the models were also fitted using the Fine-Gray method to account for competing risks of other causes of death. In addition, a further sensitivity analysis was conducted using backward elimination, with P<0.05 as the significance level for removing a covariate from the model. As a third sensitivity analysis, we included all interactions with age and heart failure and performed least absolute shrinkage and selection operator regression with cross-validation. Model discrimination and risk prediction with and without biomarkers were evaluated through the C index for survival data. 19 The C indices were optimism-adjusted using 100 bootstrap samples. A 2-sided P value of 0.05 was used as a critical value determining statistical significance, and because all analyses were exploratory, there were no adjustments for multiple comparisons. All statistical analyses were conducted using SAS software version 9.4 (SAS Institute Inc) or R version 3.1.1.
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RESULTS
Distribution of Cause-Specific Deaths
Among the 18 201 patients enrolled in the ARISTOTLE trial, 1272 (7.0%) died. In total, there were 652 (51%) cardiovascular deaths, 32 (3%) bleeding deaths, and 588 (46%) noncardiovascular, nonbleeding deaths (Figure 1 ). Among the cardiovascular causes of death, sudden cardiac death (SCD) was the most common cause of death (255; 39% of all cardiovascular deaths), followed by heart failure death (168; 26% of all cardiovascular deaths). Stroke/SE was a less common cause of death (106; 16% of all cardiovascular deaths). Of patients with available biomarker data (n=14 798), there were 1075 deaths (7.3%); the overall distribution of causes of death and the baseline demographics were similar compared with the ARISTO-TLE population (data not shown). Among noncardiovascular deaths, malignancy was the most common identified cause of death (n=126, 21% of all noncardiovascular deaths; Table III in the online-only Data Supplement).
There were differences in several baseline demographic variables by cause of death categories (Table  III in the online-only Data Supplement), including age, sex, comorbidities (including smoking, diabetes mellitus, obesity, chronic kidney disease, hypertension), CHADS 2 score, history of anemia, and history of cardiovascular disease (including prior history of heart failure, stroke/transient ischemic attack).
Cause of Death and Study Treatment Assignment
Assignment to apixaban versus warfarin appeared to have reduced stroke/SE-related deaths (39 versus 67; hazard ratio [HR], 0.58; 95% CI, 0.39-0.86; P=0.005) (Figure 2 ). There were also numerically lower rates of cardiovascular deaths (308 versus 344, P=0.13), heart failure deaths (76 versus 92, P=0. 20) , and bleeding-related deaths (15 versus 17, P=0.71) for apixaban versus warfarin, but the differences were not statistically significant.
Clinical Variables Associated With Cause of Death
A history of heart failure was most strongly associated with cardiovascular death (adjusted HR, 2.05; 95% CI, 
Distribution of Biomarkers by Cause of Death
Among the cardiovascular causes of death, patients who died of heart failure had the highest median levels of cTnT-hs and NT-proBNP at baseline (Table 1) . Patients who died of bleeding had higher GDF-15 levels. In Non-CV death refers specifically to death not attributable to CV or bleeding causes of death. Overall, 1281 patients died in the ARISTOTLE trial. In total, there were 652 (51%) CV deaths, 32 (3%) bleeding deaths, and 588 (46%) non-CV, nonbleeding deaths. Among the CV causes of death, SCD was the most common cause of death (255, 39% of all CV deaths), followed by heart failure (168, 26% of all CV deaths). Stroke/systemic embolism was a less common cause of death (106, 16% of all CV deaths). CV indicates cardiovascular; HF, heart failure; MI, myocardial infarction; SCD, sudden cardiac death; and SE, systemic embolism. *Ischemic and hemorrhagic stroke. 
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comparison, patients who died of stroke/SE had lower levels of interleukin-6, NT-proBNP, and GDF-15.
Biomarkers Associated With Cause of Death
Biomarkers were consistently among the variables most strongly associated with the different causes of death.
cTnT-hs and NT-proBNP were the strongest variables associated with cardiovascular mortality (Figure 3A ), cTnT-hs was most strongly associated with SCD ( Figure 3B ), and NT-proBNP and GDF-15 were most strongly associated with heart failure death ( Figure 3C ). For stroke/SE-related death ( Figure 3D ), a prior history of stroke/SE remained the most strongly associated variable; cTnT-hs was the second most strongly associated variable. For bleeding-related death ( Figure 3E ), GDF-15 was the most strongly associated variable. All reported associations of clinical variables and biomarkers with outcomes have been derived from multivariable models. The sensitivity analyses using Fine-Gray models to account for competing risks of other causes of death and the backwards selection of variables showed similar findings (data not shown). For all death causes except bleeding death, the least absolute shrinkage and selection operator regressions resulted in models including interactions, with unaltered results regarding the variables most strongly associated with outcomes (results not shown). For bleeding death, the least absolute shrinkage and selection operator regression included no covariates because all covariates were estimated to be 0.
Prognostic Utility of Biomarkers and Cause of Death
Models combining demographic variables with clinical data demonstrated good discrimination (Table 2) for predicting various cardiovascular causes of death (C indices range from 0.73-0.78) and bleeding death (C index, 0.67). Individual biomarkers achieved a moderate to strong discrimination for predicting different causes of death (C index ranged from 0.63-0.80). Adding biomarkers to the models containing the clinical and demographic variables improved the discrimination substantially for cause-specific death, with the highest C indices achieved in the models using all the biomarkers (Table 2) .
DISCUSSION
Among anticoagulated patients with AF, our analysis demonstrates that fatal events most commonly have cardiovascular causes, most commonly sudden cardiac death followed by heart failure and stroke/SErelated death. Apixaban, as compared with warfarin, was associated with lower rates of all causes of death (Figure 2 ), although the reduction in stroke/SE death was only different in individual fatal events that were statistically significant. Our analysis identified that the biomarkers cTnT-hs and NT-proBNP were most strongly associated with the risk of cardiovascular death. cTnThs was most strongly associated with sudden death. NTproBNP and GDF-15 were most strongly associated with heart failure death. Moreover, GDF-15 had the strongest association with fatal bleeding. The biomarkers appear to improve the discrimination of prediction of all causes of death beyond established demographic and clinical variables.
Causes of Death Among Patients Anticoagulated for AF
In this analysis of the ARISTOTLE trial, our study demonstrated that among cardiovascular causes of death, SCD followed by heart failure are the most common causes of death. These results confirm the results of prior analyses of cause of death in other pivotal phase 3 NOAC (nonvitamin-K oral anticoagulant) trials. 18, 21, 22 Similar to the earlier studies, stroke/SE and myocardial infarction remain relatively less common causes of death in anticoagulated patients with AF. A meta-analysis of >6 million patients showed that patients with AF, compared with those without AF, are at high risk of all-cause, cardiovascular, and noncardiovascular mortality. 2 Furthermore, compared with patients without AF, patients with AF have a clear increase in the risk of sudden cardiac death and heart failure death. 2, 23, 24 In totality, these results suggest that among patients anticoagulated for AF, interventions and risk factor modifications aimed at reducing mortality beyond stroke death are important in the efforts to improve the outcomes of patients with AF. The mostly strong clinical variable associated with cardiovascular death and other specific causes of 
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death (such as SCD) was a history of heart failure. Similar results have been seen in other NOAC trials 22, 25 and community cohorts. 26 Potentially, the next avenue to reduce the risk of SCD and other causes of death among patients with AF is to prevent and treat heart failure. More aggressive optimization of heart failure treatment among patients with AF may also be considered as a strategy to reduce the risk of death.
Our analysis also demonstrated that randomization to apixaban appears to reduce the risk of stroke/SE-related death. The rates of bleeding-related deaths were low in both study arms. In the RE-LY study (Randomized Evaluation of Long-Term Anticoagulation Therapy), dabigatran significantly reduced cardiovascular mortality because of a reduction in vascular death (composite of stroke/peripheral embolism, pulmonary embolism, or hemorrhage). 22 In the ENGAGE trial (Edoxaban versus warfarin in patients with atrial fibrillation trial), both edoxaban doses in comparison to warfarin reduced mortality, which was mainly explained by a reduced risk of fatal bleeding. 21 Our results therefore further reinforce the recommendations that the use of NOACs should be preferred over warfarin not least to aim for prolonged survival in appropriate patients at higher risk for fatal events. 
Association of Biomarkers With CauseSpecific Death
Our analyses demonstrated that biomarkers have some of the strongest associations with both total and causespecific deaths. Furthermore, the biomarkers appeared to improve risk stratification of individual fatal events also when added to models containing known clinical predictors such as age, sex, and history of heart failure. Prior analyses have demonstrated the incremental value of individual biomarkers including troponin, NT-proBNP, interleukin-6, and GDF-15 in predicting clinical events such as cardiovascular death and bleeding in patients with AF. 8, 10, 13, 27, 28 Combinations of these biomarkers and a few clinical variables have recently been shown to provide superior prognostication of stroke, major bleeding, and total and cardiovascular death as demonstrated by the Age, Biomarkers, and Clinical history score for bleeding, stroke, and death. 6, 17, 18 In our previous analyses, these biomarkers have been shown to be independently ORIGINAL RESEARCH ARTICLE associated with total and cardiovascular mortality in patients with AF. 9 However, they have not been previously evaluated in relation to cause-specific deaths. 17, 18 Biomarker data may suggest that different pathophysiologic pathways may be present in various disease states. [29] [30] [31] We demonstrated that cTnT-hs and NT-proBNP were strongly associated with overall cardiovascular death, suggesting that myocardial damage, myocardial dysfunction, and cardiomyocyte stress may play a dominant role in the pathophysiology of these deaths. SCD was strongly associated with cTnT-hs, NT-proBNP, and interleukin-6, suggesting that multiple pathophysiologic pathways, including myocardial ischemia, cardiomyocyte stretch, inflammation, and fibrosis, may be key components of the underlying mechanisms of SCD. NT-proBNP and GDF-15 were strongly associated with heart failure death, indicating that underlying myocardial and oxidative stress might be associated with the deterioration of myocardial function in AF. Finally, GDF-15 had the strongest association with bleeding-related death; however, the analysis was based on a low number of events. In other disease states such as heart failure, GDF-15 was showing to be a strong predictor of mortality. 32 GDF-15, a vascular marker of inflammation and oxidative stress, was recently also shown to be the strongest predictor of major bleeding risk among patients with AF in the Age, Biomarkers, and Clinical history bleeding risk score 18 ; therefore its prognostic utility in bleeding death is not unexpected even if the mechanistic details are less clear. GDF-15 may represent a more nonspecific marker of adverse outcomes because it has demonstrated prognostic value in a variety of clinical scenarios. 15 However, in the context of our analysis, GDF-15 appears to be strongly associated with bleeding death, which aligns with prior analyses demonstrating a strong association with overall bleeding events. 18 In other cohorts with cardiovascular disease, such as patients with heart failure, similar associations with biomarkers of myocardial stretch (NT-proB-NP), fibrosis (galectin-3), and inflammation (ST2) were seen with specific causes of death, including SCD and heart failure death. 33 In totality, these results may suggest that several different common pathophysiologic mechanisms may be associated with the various final causes of death regardless of the underlying disease state.
Our analyses also suggest that individual biomarkers alone have moderate to good discrimination for predicting various causes of death; however, when utilizing all biomarkers together with clinical and demographic variables, discrimination for predicting cause of death was improved. The improvement in c-statistic was significant when using all biomarkers compared with the strongest performing individual biomarkers. Therefore, this study indicates a potential utility of a combination of biomarkers (from a variety of pathophysiologic pathways) in risk stratifying for cause-specific death in patients with AF. Our analysis did not attempt to develop a clinically usable risk prediction model due to the smaller number of events seen with specific causes of death. Furthermore, future studies will need to assess the clinical effectiveness, patient acceptance, and cost-effectiveness of a multimarker strategy for risk prediction in clinical practice. However, these results suggest that future evaluation of the risk of fatal events in patients with AF may preferably utilize a spectrum of biomarkers to refine prognostication and allow for a more targeted treatment approach.
Strength and Limitations
The large sample size, high-sensitivity assays, and centrally adjudicated events are some of the major strengths Clinical variables are specified in Table II in the online-only Data Supplement. C indices including clinical variables were optimism adjusted using 100 bootstrap samples. For bleeding death, age only was included among the clinical variables. CV indicates cardiovascular; GDF-15, growth-differentiation factor-15; hs, highly sensitive; hs-TNT, highly sensitive troponin; IL, interleukin; NT-proBNP, N-terminal pro-B-type natriuretic peptide; and SE, systemic embolism.
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of this analysis; however, these results are subject to the limitations of a post hoc analysis. The improvement of c-statistic from a clinical model to a model that included biomarkers for some cause-specific deaths was modest, and the clinical applicability needs to be further developed and evaluated. The analysis for bleeding-related mortality was based on relatively fewer events. As with many clinical trials, the population enrolled in the ARISTOTLE trial may not be reflective of other populations anticoagulated with AF. A prior analysis has demonstrated the challenges in translating the findings from biomarker analyses in a population of patients with AF to other populations with AF. 34 The results of our analysis may require exploration in other nontrial populations. However, many registries have demonstrated significant similarities to the NOAC clinical trial population. 35 Future studies combining multiple clinical and testing modalities (eg, clinical variables, biomarkers, imaging, etc) will be needed to determine the optimal strategy for risk prediction.
CONCLUSIONS
In this analysis, we showed that SCD and heart failure account for the majority of cardiovascular causes of death in patients with AF with oral anticoagulation. Apixaban appears to reduce the risk of stroke-related death. Biomarkers were the strongest predictors of cause-specific death and improved the ability to discriminate among the risks for different causes of death. These findings suggest a role of biomarkers in risk stratification for cause-specific death in AF. Therefore, biomarkers might be useful to guide interventions focusing on the prevention of fatal events other than stroke and targeting treatment and prevention of cardiac risk factors such as heart failure that might improve the survival of these patients.
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